Stratos Wealth Partners’s Zevra Therapeutics ZVRA Stock Holding History
Bought
Maintained
Sold
Other funds holding ZVRA
WP
NCM
VCM
ACM
Stratos Wealth Partners's ZVRA Position: Q1 2026 in Review
Stratos Wealth Partners reduced its Zevra Therapeutics (ZVRA) stake by 0.24% in Q1 2026, selling an estimated $9.01K and leaving 408,000 shares worth $3.8M. The position accounts for 0.04% of the portfolio, ranked #389.
Stratos Wealth Partners first reported a position in ZVRA in Q4 2017 and has held it in 22 quarters since. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.
- Stratos Wealth Partners held 408,000 shares of Zevra Therapeutics worth $3.8M as of Q1 2026.
- Stratos Wealth Partners sold 1,000 Zevra Therapeutics shares in Q1 2026, an estimated $9.01K.
- Zevra Therapeutics made up 0.04% of Stratos Wealth Partners's portfolio in Q1 2026, its #389 holding.
- Stratos Wealth Partners first reported a position in Zevra Therapeutics in Q4 2017 and has held it in 22 quarters since.
- 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.
Based on Stratos Wealth Partners's 13F filing for Q1 2026, filed 28 Apr 2026.